$97.49 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
Analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report sales of $97.49 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $92.15 million to $103.91 million. Ironwood Pharmaceuticals posted sales of $94.21 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.5%. The firm is scheduled to report its next earnings report on Thursday, February 21st.
On average, analysts expect that Ironwood Pharmaceuticals will report full year sales of $321.64 million for the current fiscal year, with estimates ranging from $308.10 million to $342.30 million. For the next fiscal year, analysts expect that the firm will report sales of $419.94 million, with estimates ranging from $341.31 million to $530.18 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.24). The business had revenue of $68.69 million during the quarter, compared to analysts’ expectations of $93.48 million. During the same quarter last year, the company earned ($0.18) earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was down 20.9% on a year-over-year basis.
In related news, insider Mark G. Currie sold 130,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $18.45, for a total value of $2,398,500.00. Following the sale, the insider now owns 791,666 shares of the company’s stock, valued at $14,606,237.70. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark G. Currie sold 116,651 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $17.53, for a total value of $2,044,892.03. Following the completion of the sale, the insider now directly owns 70,680 shares in the company, valued at approximately $1,239,020.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,339 shares of company stock worth $4,475,466. 7.63% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. OppenheimerFunds Inc. grew its holdings in Ironwood Pharmaceuticals by 11.1% during the second quarter. OppenheimerFunds Inc. now owns 2,872,640 shares of the biotechnology company’s stock worth $54,925,000 after purchasing an additional 286,590 shares during the period. Aperio Group LLC grew its holdings in Ironwood Pharmaceuticals by 34.2% during the second quarter. Aperio Group LLC now owns 21,185 shares of the biotechnology company’s stock worth $405,000 after purchasing an additional 5,404 shares during the period. Meeder Asset Management Inc. bought a new position in Ironwood Pharmaceuticals during the second quarter worth about $186,000. Schwab Charles Investment Management Inc. grew its holdings in Ironwood Pharmaceuticals by 6.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 722,555 shares of the biotechnology company’s stock worth $13,816,000 after purchasing an additional 44,157 shares during the period. Finally, Public Employees Retirement System of Ohio grew its holdings in Ironwood Pharmaceuticals by 11.3% during the second quarter. Public Employees Retirement System of Ohio now owns 120,370 shares of the biotechnology company’s stock worth $2,301,000 after purchasing an additional 12,175 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.
Shares of IRWD traded down $0.20 during midday trading on Wednesday, hitting $11.88. The stock had a trading volume of 1,677,504 shares, compared to its average volume of 1,784,796. Ironwood Pharmaceuticals has a twelve month low of $11.62 and a twelve month high of $21.20. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -12.77 and a beta of 1.33.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
See Also: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.